tiziana-logo.png
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
August 01, 2022 08:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
tiziana-logo.png
Tiziana Life Sciences Appoints Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
July 18, 2022 06:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Announces Resignation of CEO
July 15, 2022 16:15 ET | Tiziana Life Sciences Ltd.
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
June 17, 2022 16:30 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
June 10, 2022 08:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences PLC (TLSA: NASDAQ) Releases Research Report: Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:53 ET | Tiziana Life Sciences Ltd.
Zacks Small-Cap Research Note By John D. Vandermosten, CFA NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
Tiziana Life Sciences Announces An Interview on Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:25 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug...
Tiziana Life Sciences PLC (TLSA: NASDAQ) Clinical Improvements for 2nd SPMS Patient
June 09, 2022 12:04 ET | Tiziana Life Sciences Ltd.
Research Note Clinical Results for Second SPMS Patient NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences PLC (NASDAQ: TLSA) announced positive clinical results for its second...
tiziana-logo.png
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
June 09, 2022 07:00 ET | Tiziana Life Sciences Ltd.
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
tiziana-logo.png
Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab
June 08, 2022 07:00 ET | Tiziana Life Sciences Ltd.
A second patient also showed clinical improvements in the Positron Emission Tomography (PET) imaging analysis, neurologic exam, and in the Timed 25-Foot Walk test, following three months of treatment....